Yarrow Bioscience, Inc. (YARW) shareholders
Close on Nov 17, 2026Market cap $37.94MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (6.00%), Wilmot B. Harkey (6.00%) | 2,000,000 | 6.00% | 13G (passive) | Mar 31, 2026 |
| Eventide Asset Management, LLC Joint filing with Finny Kuruvilla, M.D. Ph. D. (9.99%), Robin C. John (9.99%) | 1,849,597 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| Bellevue Asset Management AG Joint filing with Bellevue Group AG (10.60%) | 1,000,000 | 10.60% | 13G (passive) | Sep 10, 2026 |
| Raymond Debbane Joint filing with Invus Public Equities, L.P. (6.30%), Invus Public Equities Advisors, LLC (6.30%) and 2 more | 675,000 | 7.20% | 13G (passive) | Sep 11, 2026 |
| Logos Global Management GP LLC Joint filing with Logos Global Management LP (10.70%), Arsani William (10.70%) and 2 more | 286,308 | 10.70% | 13G (passive) amendment | Jul 31, 2026 |
| venBio Global Strategic Fund V, L.P. Joint filing with venBio Global Strategic GP V, LLC (9.99%) | 279,340 | 9.99% | 13G (passive) | Jul 27, 2026 |
| Logos Global Management LP Joint filing with Logos Global Management GP LLC (9.90%), Arsani William (9.90%) and 5 more | 276,704 | 9.90% | 13G (passive) | Jul 27, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (9.99%), Joseph Edelman (9.99%) | 266,756 | 9.99% | 13G (passive) | Jul 27, 2026 |
| JANUS HENDERSON GROUP Ltd. | 266,712 | 9.99% | 13G (passive) | Jul 31, 2026 |
| RTW Fund Group GP, LLC Joint filing with Roderick Wong (9.99%) | 266,307 | 9.99% | 13G (passive) | Jul 27, 2026 |
| Orbimed Advisors LLC Joint filing with OrbiMed Capital GP X LLC (8.73%), OrbiMed Capital GP X, LP (8.73%) | 266,306 | 9.97% | 13D (active) | Jul 27, 2026 |
| Len Blavatnik Joint filing with AI Biotechnology LLC (6.02%), Access Industries Holdings LLC (6.02%) and 1 more | 178,180 | 6.02% | 13D (active) amendment | Jul 27, 2026 |
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (8.80%) | 59,000 | 8.80% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of YARW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 80,000 | 3.00% | $2.60M | +40,000 | 0.04% |
| ADAR1 Capital Management, LLC | 59,000 | 2.21% | $1.92M | +37,722 | 0.09% |
| Lynx1 Capital Management LP | 32,574 | 1.22% | $1.06M | – | 0.12% |
| Shay Capital LLC | 29,133 | 1.09% | $947.84K | −3,072 | 0.06% |
| T3 Companies, LLC | 18,900 | 0.71% | $614.91K | – | 0.66% |
| Braidwell LP | 18,322 | 0.69% | $596.09K | – | 0.02% |
| KVP Capital Advisors, LP | 10,011 | 0.37% | $325.71K | – | 0.24% |
| Citadel Advisors LLC | 9,369 | 0.35% | $304.83K | −920 | 0.00% |
| Two Sigma Investments, LP | 8,776 | 0.33% | $285.54K | +248 | 0.00% |
| Acadian Asset Management LLC | 7,636 | 0.29% | $248.00K | – | 0.00% |
| Ikarian Capital, LLC | 5,298 | 0.20% | $172.38K | – | 0.02% |
| Vanguard Capital Management LLC | 5,291 | 0.20% | $172.23K | – | 0.00% |
| Geode Capital Management, LLC | 5,164 | 0.19% | $168.02K | −1,290 | 0.00% |
| Vanguard Fiduciary Trust Co | 3,669 | 0.14% | $119.42K | – | 0.00% |
| Susquehanna International Group, Llp | 2,379 | 0.09% | $77.41K | +1,223 | 0.00% |
| Rangeley Capital, LLC | 2,261 | 0.08% | $73.57K | −100 | 0.07% |
| XTX Topco Ltd | 1,574 | 0.06% | $51.22K | −1,594 | 0.00% |
| Gsa Capital Partners Llp | 1,431 | 0.05% | $47.00K | New | 0.00% |
| Superstring Capital Management LP | 1,225 | 0.05% | $39.87K | New | 0.03% |
| UBS Group AG | 1,172 | 0.04% | $38.15K | −2,424 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 0M | 11.6% | 6 / 7 | 9 / 4 | 0M | 0M |
| Q1 2026 | 44 | 0M | 10.8% | 8 / 11 | 4 / 4 | 0M | 0M |
| Q4 2025 | 43 | 0M | 6.9% | 13 / 10 | 8 / 3 | 0M | 0M |
| Q3 2025 | 33 | 0M | 2.9% | 7 / 8 | 6 / 18 | 0M | 0M |
| Q2 2025 | 44 | 0M | 6.0% | 14 / 9 | 12 / 7 | 0M | 0M |
| Q1 2025 | 37 | 0M | 5.3% | 7 / 14 | 7 / 4 | 0M | 0M |
| Q4 2024 | 34 | 0M | 5.3% | 9 / 9 | 8 / 6 | 0M | 0M |
| Q3 2024 | 32 | 0M | 5.7% | 3 / 4 | 12 / 0 | 0M | 0M |
| Q2 2024 | 30 | 0M | 6.0% | 2 / 12 | 9 / 2 | 0M | 0M |
| Q1 2024 | 30 | 0M | 5.8% | 4 / 7 | 6 / 6 | 0M | 0M |
| Q4 2023 | 32 | 0M | 5.9% | 13 / 10 | 3 / 1 | 0M | 0M |
| Q3 2023 | 20 | 0M | 0.3% | 3 / 4 | 6 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Rebecca Frey | Chief Executive Officer, Director | – | – | Oct 30, 2026 |
| David Domzalski | PRESIDENT AND CEO, Director | 347,174 | 13.00% | Jul 24, 2026 |
| Tyler Zeronda | Chief Financial Officer | 74,918 | 2.81% | Oct 30, 2026 |
| Rachael Alford | Chief Operating Officer | – | – | Oct 30, 2026 |
| Steven Ryder | Chief Medical Officer | – | – | Oct 30, 2026 |
| Lori Payton | Chief Development Officer | – | – | Oct 30, 2026 |
| Mutya Harsch | CHIEF LEGAL OFFICER AND GC | 95,918 | 3.59% | Jul 24, 2026 |
| Iain Stuart | CHIEF SCIENTIFIC OFFICER | 95,944 | 3.59% | Jul 24, 2026 |
| Capital GP X. LLC OrbiMed | Director | – | – | Jul 29, 2026 |
| Genesis GP LLC OrbiMed | Director | – | – | Jul 29, 2026 |
| Steven L. Hoerter | Director | – | – | Jul 29, 2026 |
| Advisors Llc Orbimed | Director | 233,019 | 8.73% | Jul 29, 2026 |
| Mona Ashiya | Director | 33,287 | 1.25% | Jul 29, 2026 |
| Peter B. Silverman | Director | – | – | Jul 29, 2026 |
| William Richard White | Director | – | – | Jul 29, 2026 |
| Sven Ante Lundberg | Director | – | – | Jul 29, 2026 |
| Elisabeth Sandoval Little | Director | – | – | Dec 15, 2025 |
| Steven L. Basta | Director | 853,942 | 31.99% | Dec 15, 2025 |
| Patrick G. Lepore | Director | 51,472 | 1.93% | Dec 15, 2025 |
| Sharon Barbari | Director | 75,000 | 2.81% | Dec 15, 2025 |
| Christine Borowski | Director | – | – | Dec 13, 2024 |
| Anthony D. Bruno | Director | 120,123 | 4.50% | Dec 13, 2024 |
| RTW Fund Group GP, LLC | 10% owner | 399,597 | 14.97% | Jul 30, 2026 |
| Roderick Wong | 10% owner | 266,307 | 9.97% | Jul 30, 2026 |
| Life Sciences Master Fund Ltd Perceptive | 10% owner | 5,435,057 | 203.58% | Jul 29, 2026 |
| Advisors Llc Perceptive | 10% owner | 266,309 | 9.98% | Jul 29, 2026 |
| Joseph Edelman | 10% owner | 4,935,057 | 184.85% | Jul 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Roderick Wong 10% owner | Jul 29, 2026 | Other | −133,290 | – | – | 266,307 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jul 23, 2026 | Tax withholding | −22,516 | $0.90 | $20.26K | 95,918 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Jul 23, 2026 | Tax withholding | −15,405 | $0.90 | $13.86K | 95,944 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Jul 23, 2026 | Tax withholding | −22,516 | $0.90 | $20.26K | 74,918 |
| David Domzalski PRESIDENT AND CEO, Director | Jul 23, 2026 | Tax withholding | −79,391 | $0.90 | $71.45K | 347,174 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Jun 30, 2026 | Tax withholding | −3,464 | $0.65 | $2.25K | 97,434 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Jun 30, 2026 | Tax withholding | −2,370 | $0.65 | $1.54K | 111,349 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jun 30, 2026 | Tax withholding | −3,464 | $0.65 | $2.25K | 118,434 |
| David Domzalski PRESIDENT AND CEO, Director | Jun 30, 2026 | Tax withholding | −12,214 | $0.65 | $7.94K | 426,565 |
| David Domzalski PRESIDENT AND CEO, Director | May 29, 2026 | Award | +30,791 | $0.31 | $9.55K | 438,779 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Mar 31, 2026 | Tax withholding | −4,007 | $0.60 | $2.40K | 121,898 |
| David Domzalski PRESIDENT AND CEO, Director | Mar 31, 2026 | Tax withholding | −14,232 | $0.60 | $8.54K | 401,976 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Mar 31, 2026 | Tax withholding | −4,007 | $0.60 | $2.40K | 99,788 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Mar 31, 2026 | Tax withholding | −2,876 | $0.60 | $1.73K | 112,363 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Dec 31, 2025 | Tax withholding | −3,579 | $0.58 | $2.08K | 125,905 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Dec 31, 2025 | Tax withholding | −2,448 | $0.58 | $1.42K | 115,239 |
| David Domzalski PRESIDENT AND CEO, Director | Dec 31, 2025 | Tax withholding | −12,684 | $0.58 | $7.36K | 416,208 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Dec 31, 2025 | Tax withholding | −7,858 | $0.58 | $4.56K | 103,795 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Sep 30, 2025 | Tax withholding | −2,453 | $0.34 | $834 | 117,687 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Sep 30, 2025 | Tax withholding | −3,581 | $0.34 | $1.22K | 129,484 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Sep 30, 2025 | Tax withholding | −3,420 | $0.34 | $1.16K | 111,653 |
| David Domzalski PRESIDENT AND CEO, Director | Sep 30, 2025 | Tax withholding | −12,676 | $0.34 | $4.31K | 428,892 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Jun 30, 2025 | Tax withholding | −3,420 | $1.65 | $5.64K | 115,073 |
| David Domzalski PRESIDENT AND CEO, Director | Jun 30, 2025 | Tax withholding | −12,676 | $1.65 | $20.92K | 441,568 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Jun 30, 2025 | Tax withholding | −2,453 | $1.65 | $4.05K | 120,140 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jun 30, 2025 | Tax withholding | −3,581 | $1.65 | $5.91K | 133,065 |
| David Domzalski PRESIDENT AND CEO, Director | Jun 2, 2025 | Award | +8,681 | $0.81 | $7.03K | 454,244 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jun 2, 2025 | Award | +1,145 | $0.81 | $927 | 136,646 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Mar 31, 2025 | Tax withholding | −8,828 | $1.58 | $13.95K | 135,501 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Mar 31, 2025 | Tax withholding | −8,399 | $1.58 | $13.27K | 118,493 |
| David Domzalski PRESIDENT AND CEO, Director | Mar 31, 2025 | Tax withholding | −30,498 | $1.58 | $48.19K | 445,563 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Mar 31, 2025 | Tax withholding | −6,044 | $1.58 | $9.55K | 122,593 |
| Patrick G. Lepore Director | Jan 15, 2025 | Buy | +15,000 | $2.92 | $43.80K | 51,472 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Dec 31, 2024 | Tax withholding | −4,697 | $3.35 | $15.73K | 144,329 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Dec 31, 2024 | Tax withholding | −4,675 | $3.35 | $15.66K | 126,892 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Dec 31, 2024 | Tax withholding | −4,857 | $3.35 | $16.27K | 128,637 |
| David Domzalski PRESIDENT AND CEO, Director | Dec 31, 2024 | Tax withholding | −24,536 | $3.35 | $82.20K | 476,061 |
| David Domzalski PRESIDENT AND CEO, Director | Nov 30, 2024 | Award | +3,901 | $2.10 | $8.19K | 500,597 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Sep 30, 2024 | Tax withholding | −84 | $1.88 | $158 | 131,567 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Sep 30, 2024 | Tax withholding | −109 | $1.88 | $205 | 133,494 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Sep 30, 2024 | Tax withholding | −105 | $1.88 | $197 | 149,026 |
| David Domzalski PRESIDENT AND CEO, Director | Sep 30, 2024 | Tax withholding | −685 | $1.88 | $1.29K | 496,696 |
| David Domzalski PRESIDENT AND CEO, Director | Jul 1, 2024 | Tax withholding | −935 | $1.92 | $1.80K | 497,654 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Jul 1, 2024 | Tax withholding | −138 | $1.92 | $265 | 133,603 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jul 1, 2024 | Tax withholding | −143 | $1.92 | $275 | 149,131 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Jul 1, 2024 | Tax withholding | −92 | $1.92 | $177 | 131,651 |
| David Domzalski PRESIDENT AND CEO, Director | May 31, 2024 | Award | +4,429 | $2.16 | $9.57K | 498,589 |
| David Domzalski PRESIDENT AND CEO, Director | Apr 1, 2024 | Tax withholding | −1,004 | $3.08 | $3.09K | 494,160 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Apr 1, 2024 | Tax withholding | −161 | $3.08 | $496 | 149,274 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Apr 1, 2024 | Tax withholding | −157 | $3.08 | $484 | 133,741 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Apr 1, 2024 | Tax withholding | −94 | $3.08 | $290 | 131,743 |
| David Domzalski President and CEO, Director | Jan 2, 2024 | Tax withholding | −1,004 | $2.28 | $2.29K | 495,164 |
| Tyler Zeronda Chief Financial Officer | Jan 2, 2024 | Tax withholding | −93 | $2.28 | $212 | 131,837 |
| Iain Stuart Chief Scientific Officer | Jan 2, 2024 | Tax withholding | −157 | $2.28 | $358 | 133,898 |
| Mutya Harsch Chief Legal Officer and GC | Jan 2, 2024 | Tax withholding | −161 | $2.28 | $367 | 149,435 |
| David Domzalski President and CEO, Director | Jan 1, 2024 | Award | +225,000 | – | – | 496,168 |
| Tyler Zeronda Chief Financial Officer | Jan 1, 2024 | Award | +62,500 | – | – | 131,930 |
| Iain Stuart Chief Scientific Officer | Jan 1, 2024 | Award | +62,500 | – | – | 134,055 |
| Mutya Harsch Chief Legal Officer and GC | Jan 1, 2024 | Award | +62,500 | – | – | 149,596 |
| Tyler Zeronda Chief Financial Officer | Dec 13, 2023 | Award | +62,500 | – | – | 69,430 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 4 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Yarrow Bioscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,180 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?